

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETAR

02 AUG

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Abbott Laboratories			
2. Address <input checked="" type="checkbox"/> Check if different than previously reported 1399 New York Avenue, N.W., Suite 200, Washington, D.C. 20005			
3. Principal Place of Business (if different from line 2) City: Abbott Park		State/Zip (or Country) IL 60064	
4. Contact Name Cynthia B. Sensibaugh	Telephone (202) 378-2035	E-mail (optional) CYNTHIA.SENSIBAUGH @ ABBOTT.COM	5. Senate ID # 66
7. Client Name <input checked="" type="checkbox"/> Self Self			6. House ID # 3000

**TYPE OF REPORT** 8. Year 2002 Midyear (January 1-June 30)  OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_

11. No Lobbyin

**INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**

<p align="center"><b>12. Lobbying Firms</b></p> <p><b>INCOME</b> relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p><b>EXPENSES</b> relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>1,300,000.00</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 60 Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 16 Internal Revenue Code</p>
--	---

Signature \_\_\_\_\_

Printed Name and Title



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

1. H.R. 5263, S. 2801 - Agriculture Appropriations FY 2003, funding for Women, Infants and Children program.  
2. House draft bill, S. 2766 - Labor, HHS appropriations FY 2003, funding for state AIDS Drug Assistance programs under the Ryan White Act.

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

1. S. 812 - Greater Access to Affordable Pharmaceuticals Act of 2001  
2. Proposals to establish compulsory licensing for HIV drugs in developing countries

17. House(s) of Congress and Federal agencies contacted  Check if None

Senate  
House

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Cynthia B. Sensibaugh	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

1. S. 2244, Prescription Drug Price Parity for Americans Act
2. Proposal to raise awareness of health risks of obesity
3. H.R. 3448, Public Health, Security and Bioterrorism Preparedness and Response Act of 2002, Title V, Subtitle A, Prescription Drug User Fee Amendments of 2002

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate  
Health and Human Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Cynthia B. Sensibaugh	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_





Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

1. H.R. 1624, S. 913 - Access to Cancer Therapies Act of 2001
2. H.R. 4954, Medicare Modernization and Prescription Drug Act of 2002
3. S. 2625, Medicare Outpatient Prescription Drug Act of 2002
4. S.2, 21st Century Medicare Act
5. H.R. 1089, S. 554 - Access to Innovation for Medicare Patients Act of 2001
6. H.R. 1798, S. 1066 - Medicare Patient Access to Preventive and Diagnostic Tests Act
7. H.R. 3391 - Medicare Regulatory and Contracting Reform Act of 2001, provision relating to methods for determining payment basis for new lab tests

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate  
Centers for Medicare and Medicaid Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Cynthia B. Sensibaugh	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

- 8. S. 1738 - Medicare Appeals, Regulatory and Contracting Improvement Act, provision relating to methods for determining payment basis for new lab tests.
- 9. Medicare local medical review policies in South Carolina, Florida, Illinois, Ohio, Kentucky, Indiana, Virginia, Texas Louisiana, Oklahoma, New Mexico and Colorado to reduce reimbursement for vitamin D therapy
- 10. Ensure adequate Medicare reimbursement for new technologies to increase the safety of the blood supply
- 11. President's FY 2003 budget proposal to change the Medicaid rebate system

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate  
Centers for Medicare and Medicaid Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Cynthia B. Sensibaugh	
Rosemary T. Haas	
.....	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code RET (one per page)

16. Specific lobbying issues

1. S. 1992 - Protecting America's Pension Act of 2002
2. H.R. 3669 - Employee Retirement Savings Bill of Rights
3. H.R. 3762 - Pension Security Act of 2002
4. S. 1838 - Pension Protection and Diversification Act of 2001

17. House(s) of Congress and Federal agencies contacted  Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

1.H.R. 1786, S. 847 - To impose tariffs on certain casein and milk protein concentrates

17. House(s) of Congress and Federal agencies contacted  Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_





Registrant Name Abbott Laboratories Client Name Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and provide information as requested. Attach additional page(s) as needed.

15. General issue area code UTI (one per page)

16. Specific lobbying issues

1.H.R. 4 - Safe Act of 2001  
2. S. 517 - National Laboratories Partnership Improvement Act of 2001

17. House(s) of Congress and Federal agencies contacted

Check if None

House  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Abbott Laboratories Client Name Self

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

1399 New York Avenue, N.W., Suite 200, Washington, D.C. 20005

21. Client new principal place of business (if different from line 20)

City \_\_\_\_\_ State/Zip (or Country) \_\_\_\_\_

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

Mark E. Barmak

**ISSUE UPDATE**

24. General lobbying issues previously reported that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Bu (city and state or co)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that **no longer owns, or controls, or is affiliated** with the registrant affiliated organization

Signature Cynthia B. Sensibaugh Date 08-14-02

